Publications

Here you can find links to publications connected to the K.G. Jebsen Colorectal Cancer Research Centre.

Eilertsen et al. 2020. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Lett. 469: 246-255
Araghi et al. 2020. Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut [Online ahead of print]
Lopes et al. 2020. A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis. Gastric Cancer [Online ahead of print]
Bruun et al. 2020. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Clin. Cancer Res. [Online ahead of print]
Brunsell et al. 2020. High concordance and negative prognostic impact of RAS/BRAF/PIK3CA mutations in multiple resected colorectal liver metastases. Clin. Colorectal Cancer [Online ahead of print]
Sveen et al. 2019. Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes. Ann. Oncol. 30(11): 1682-1685
Miranda et al. 2019. Cancer stemness, intratumoral heterogeneity, and immune response across cancers. PNAS 116(18): 9020-9029
Burocziova et al. 2019. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. Cell Death. Dis. 10(11): 818
Lopes et al. 2019. Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. Lab. Invest. [Epub ahead of print]
Dienstmann et al. 2019. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Ann. Oncol. 30(10): 1622-1629
Totland et al. 2019. Regulation of gap junction intercellular communication by connexin ubiquitination: physiological and pathophysiological implications. Cell. Mol. Life Sci. [Epub ahead of print]
Eide et al. 2019. Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties. Int. J. Cancer 144(11): 2843-2853
Glaire et al. 2019. Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. Br. J. Cancer [Epub ahead of print]
Brunsell et al. 2019. Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. Eur. J. Surg. Oncol. [Epub ahead of print]
Berg et al. 2019. Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. Oncogene [Epub ahead of print]
Sveen A, Kopetz S, Lothe RA. 2019. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat. Rev. Clin. Oncol. [Epub ahead of print]
Marcuello et al. 2019. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol. Asp. Med. [Epub ahead of print]
Smeby et al. 2019. Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis 8(6): 35
Kryeziu et al., 2019. Combination therapies with HSP90 inhibitors against colorectal cancer. BBA Reviews on Cancer, 1871(2): 240-247
Eilertsen IA et al., 2019. Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer. Int J Cancer, 144(4): 841-847
Røsok et al., 2019. Characterization of early recurrences following liver resection by ALPPS and two stage hepatectomy in patients with colorectal liver-metastases and small future liver remnants; a translational substudy of the LIGRO-RCT. HPB (Oxford), [Epub ahead of print]
Röhrl et al., 2019. Symptoms during chemotherapy in colorectal cancer patients. Support Care Cancer, [Epub ahead of print]
Aasen et al., 2019. Connexins in cancer: bridging the gap to the clinic. Oncogene [Epub ahead of print]
Rusten et al., 2019. Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. Br J Radiol, [Epub ahead of print]
Battersby et al., and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery. Colorectal Dis, Suppl 6: 58-68
Bhangu et al., and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesorectal excision (TaTME). Colorectal Dis, Suppl 6: 33-46
Glasbey et al and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. The impact of conversion on the risk of major complication following laparoscopic colonic surgery: an international, multicentre prospective audit. Colorectal Dis, Suppl 6: 69-89
Glasbey et al and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. Association of mechanical bowel preparation with oral antibiotics and anastomotic leak following left sided colorectal resection: an international, multi-centre, prospective audit. Colorectal Dis, Suppl 6: 15-32
Sánchez-Guillén et al and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. Safety of primary anastomosis following emergency left sided colorectal resection: an international, multi-centre prospective audit. Colorectal Dis, Suppl 6: 47-57
Gleditsch et al., 2018. Surgical options and trends in treating rectal prolapse: long-term results in a 19-year follow-up study. Langenbecks Arch Surg, 403(8): 991-998
Benitez Majano et al., 2019. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncology 20: 74–87
Thomsen et al., 2018. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. Br J Cancer 118(12):1609-1616
Mezheyeuski et al., 2018. Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Arch, 472(3): 395-405
Eide et al., 2018. Long non-coding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties. Int J Cancer, [Epub ahead of print]
Guren et al., 2018. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clin Colorectal Cancer, [Epub ahead of print]
Claassen YHM et al., 2018. Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. Br J Cancer, 119, 517–522
Ommundsen N et al., 2018. Post-discharge complications in frail older patients after surgery for colorectal cancer. Eur J Surg Oncol, [Epub ahead of print]
Bretthauer M et al., 2018. Uterine morcellation and survival in uterine sarcomas. Eur J Cancer, 101: 62-8
Pedersen IB et al., 2018. Polypectomy techniques among gastroenterologists in Norway – a nationwide survey. Endosc Int Open, 6(7): E812-20
Høland M et al., 2018. Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. Mod Pathol, [Epub ahead of print]
Bruun J et al., 2018, Prognostic, predictive and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Mol Oncol, [Epub ahead of print]
Vedeld HM et al., 2018. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin Epigenetics, 10: 70
Vermeer NCA et al., 2018. Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison. Oncologist, [Epub ahead of print]
Smeby J et al., 2018. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann Oncol, 29(5): 1227-34
Pharo HD et al., 2018. A robust internal control for high-precision DNA methylation analyses by droplet digital PCR. Clin Epigenetics, 10: 24
Oltedal S et al., 2018. The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer. Transl Oncol, 11(2): 436-43
Holme Ø et al., 2018. Endoscopy assistants influence the quality of colonoscopy.Endoscopy [Epub ahead of print]
Danielsen HE et al., 2018. Prognostic markers for colorectal cancer: estimating ploidy and stroma. Ann Oncol, 29(3): 616-23
Vedeld HM et al., 2018. Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives. Semin Cancer Biol, 51: 36-49
Sveen A et al., 2018. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clin Cancer Res, 24(4): 794-806
Berg KCG et al., 2017. Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies. Mol Cancer, 16(1): 116
Dienstmann R et al., 2017. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol, 28(5): 1023-31
Eide PW et al., 2017. CMScaller: An R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Sci Rep, 7(1): 16618
Øines M et al., 2017. Epidemiology and risk factors of colorectal polyps. Best Pract Res Clin Gastroenterol, 31(4): 419-24
Emilsson L et al., 2017. Colorectal cancer death after adenoma removal in Scandinavia. Scand J Gastroenterol, 52(12): 1377-84
Byskov CS et al., 2017. The normal tissue sparing potential of an adaptive plan selection strategy for re-irradiation of recurrent rectal cancer. Physics and Imaging in Radiation Oncology, 3: 43–48
Rusten E et al., 2017. Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography. Radiat Oncol, 12(1): 147
Lind GE et al., 2017. Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients. Clin Epigenetics, 9: 97
Landskron J et al. 2017. C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. PLoS One. 2017 Jul 31;12(7):e0182030.
Ommundsen N et al. 2017. Preoperative geriatric assessment and tailored interventions in frail older patients with colorectal cancer. A randomised controlled trial. Colorectal Dis. 2017 Jun 26. [Epub ahead of print]
Lind GE et al. 2017. Details matter: the role of genomic location and assay standardization in DNA methylation analyses. Epigenomics. 2017 Jul;9(7):933-935.
Garborg K et al. 2017. Quality Indicators in Colonoscopy. Curr Treat Options Gastroenterol. 2017 Jul 12. [Epub ahead of print]
Totland MZ et al. 2017. The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin43 to promote loss of gap junctions. J Cell Sci. 2017 Sep 1;130(17):2867-2882.
Guren TK et al. 2017. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. Br J Cancer. 2017 May 9;116(10):1271-1278.
Sclafani F et al. 2017. Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. Int J Cancer. 2017 Jan 15;140(2):431-439.
Hoff G et al. 2017. Cecum intubation rate as quality indicator in clinical versus screening colonoscopy. Endosc Int Open. 2017 Jun;5(6):E489-E495.
Holme Ø et al. 2017. Authors' reply to Doherty and Hawkins. BMJ. 2017 Mar 10;356:j1267.
Kaminski MF et al. 2017. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2017 Apr;49(4):378-397.
Bretthauer M et al. 2017. America, We Are Confused: The Updated U.S. Preventive Services Task Force Recommendation on Colorectal Cancer Screening. Ann Intern Med. 2017 Jan 17;166(2):139-140.
Astrup GL et al. 2017. Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncol. 2017 Mar;56(3):462-470.
Berg KCG et al. 2017. Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies. Mol Cancer. 2017 Jul 6;16(1):116.
Vedeld HM et al. 2017. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. Int J Cancer. 2017 Sep 1;141(5):967-976.
Sveen A et al. 2017. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Med. 2017 May 24;9(1):46.
Thomsen M et al. 2017. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. Eur J Cancer. 2017 Aug;81:26-35.
Åsli LM et al. 2017. Preoperative chemoradiotherapy for rectal cancer and impact on outcomes – A population-based study. Radiother Oncol. 2017 Jun;123(3):446-453.
Hoff G et al. 2017. Patient-reported adverse events after colonoscopy in Norway. Endoscopy. 2017 Aug;49(8):745-753.
Labori KJ et al. 2017. Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short term surgical outcomes, overall and recurrence free survivals. Colorectal Dis. 2017 Aug;19(8):731-738.
Dienstmann R et al. 2017. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017 May 1;28(5):1023-1031.
Stornes T et al. 2016. National Early Rectal Cancer Treatment Revisited. Dis Colon Rectum. 2016 Jul;59(7):623-9.
Boye K et al. 2016. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Med. 2016 Aug;5(8):1840-9.
Gleditsch D et al. 2016. Managing Malignant Colorectal Obstruction with Self-Expanding Stents. A Closer Look at Bowel Perforations and Failed Procedures. J Gastrointest Surg. 2016 Sep;20(9):1643-9.
Løberg M et al. 2016. Commentary: "Randomize, Then Consent" or "Consent, Then Randomize"?: Revitalizing the Issue of Preconsent Randomization. Epidemiology. 2016 May;27(3):393-4.
Holme Ø et al. 2016. Methodological considerations for surveillance in GI practice. Best Pract Res Clin Gastroenterol. 2016 Dec;30(6):867-878.
Adami HO et al. 2017. Are rapidly growing cancers more lethal? Eur J Cancer. 2017 Feb;72:210-214. Epub 2016 Dec 30.
Emilsson L et al. 2017. Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Aliment Pharmacol Ther. 2017 Jan;45(2):193-204. Epub 2016 Nov 17.
Kaminski MF et al. 2016. Cancer surveillance in gastroenterology practice. Best Pract Res Clin Gastroenterol. 2016 Dec;30(6):853-854.
Gjøstein DK et al. 2016. Incentives and participation in a medical survey. Tidsskr Nor Laegeforen. 2016 Jul 5;136(12-13):1082-7.
Rees CJ et al. 2016. Expert opinions and scientific evidence for colonoscopy key performance indicators. Gut. 2016 Dec;65(12):2045-2060.
Garborg K et al. 2017. Gradual stiffness versus magnetic imaging-guided variable stiffness colonoscopes: A randomized noninferiority trial. United European Gastroenterology Journal 2017, Vol. 5(1) 128–133.
Jørgensen KJ et al. 2016. Overview of guidelines on breast screening: Why recommendations differ and what to do about it. Breast. 2017 Feb;31:261-269.
Rutter MD et al. 2016. The European Society of Gastrointestinal Endoscopy Quality Improvement Initiative: developing performance measures. United European Gastroenterol J. 2016 Feb;4(1):30-41.
Rees CJ et al. 2016. European Society of Gastrointestinal Endoscopy – Establishing the key unanswered research questions within gastrointestinal endoscopy. Endoscopy. 2016 Oct;48(10):884-891.
Bretthauer M et al. 2016. Requirements and standards facilitating quality improvement for reporting systems in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2016 Mar;48(3):291-4.
Bisschops R et al. 2016. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2016 Sep;48(9):843-64.
Bisschops R et al. 2016. Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative. United European Gastroenterol J. 2016 Oct;4(5):629-656.
Berstad P et al. 2016. Lifestyle changes at middle age and mortality: a population-based prospective cohort study. J Epidemiol Community Health. 2017 Jan;71(1):59-66. Epub 2016 Jun 16.
Pharo HD et al. 2016. Experimental factors affecting the robustness of DNA methylation analysis. Sci Rep. 2016 Sep 27;6:33936.
Fykerud TA et al. 2016. Mitotic cells form actin-based bridges with adjacent cells to provide intercellular communication during rounding. Cell Cycle. 2016 Nov;15(21):2943-2957.
Mezheyeuski A et al. 2016. Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. Oncotarget. 2016 Jul 5;7(27):41948-41958.
Tarpgaard LS et al. 2016. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. Oncotarget. 2016 Sep 13;7(37):59441-59457.
Thomsen M et al. 2016. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget. 2016 Nov 15;7(46):75013-75022.
Røhrl K et al. 2016. No Differences in Symptom Burden Between Colorectal Cancer Patients Receiving Curative Versus Palliative Chemotherapy. J Pain Symptom Manage. 2016 Oct;52(4):539-547.
Holme Ø et al. 2017. Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. BMJ. 2017 Jan 13;356:i6673.
Glimelius B et al. 2016. Two countries – Two treatment strategies for rectal cancer. Radiother Oncol. 2016 Dec;121(3):357-363.
García-Albéniz X et al. 2016. Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years: A Prospective Observational Study. Ann Intern Med. 2017 Jan 3;166(1):18-26.
Domingo E et al. 2016. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology & Hepatology. Volume 1, No. 3, p207–216, November 2016
Sveen A et al. 2016. Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. PLoS Genet. 2016 Jul 29;12(7):e1006225.
Cameron MG et al. 2016. Palliative pelvic radiotherapy for symptomatic rectal cancer – a prospective multicenter study. Acta Oncol. 2016 Dec;55(12):1400-1407.
Rønning B et al. 2016. Quality of life in older and frail patients after surgery for colorectal cancer – A follow-up study. J Geriatr Oncol. 2016 May;7(3):195-200.
Holme Ø et al. 2016. Pain and sedation during colonoscopy – a never ending story. Endosc Int Open. 2016 May;4(5):E538-9.
Bretthauer M et al. 2016. Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial. JAMA Intern Med. 2016 Jul 1;176(7):894-902.
Garborg K et al. 2016. Cecal intubation failure: Refer or change technique? Gastrointest Endosc. 2016 June;83(6):1245–1247
Jover R et al. 2016. Rationale and design of the European Polyp Surveillance (EPoS) trials. Endoscopy. 2016 Jun;48(6):571-8.
Bretthauer M et al. 2016. Reporting systems in gastrointestinal endoscopy: Requirements and standards facilitating quality improvement: European Society of Gastrointestinal Endoscopy position statement. United European Gastroenterol J. 2016 Apr;4(2):172-6.
Bretthauer M et al. 2016. Who Is for CO2? Slow Adoption of Carbon Dioxide Insufflation in Colonoscopy. Ann Intern Med. 2016 Jul 19;165(2):145-6.
Adami H-O et al. 2016. The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut. 2016 Jun;65(6):889-93.
Cekaite L et al. 2016. MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget. 2016 Feb 9;7(6):6476-505.
Hoff AM et al. 2015. Novel RNA variants in colorectal cancers. Oncotarget. 2015 Nov 3;6(34):36587-602.
Tarpgaard LS et al. 2015. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. Int J Cancer. 2015 Nov 15;137(10):2470-7.
Leon O et al. 2015. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur J Cancer. 2015 Dec;51(18):2740-6.
Kjersem JB et al. 2016. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. Pharmacogenomics J. 2016 Jun;16(3):272-9. Epub 2015 Aug 11.
Hassan C et al. 2016. Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis. Gut. 2016 May;65(5):806-20. Epub 2015 Feb 13.
Dueland S et al. 2015. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015 May;261(5):956-60.
Bretthauer M et al. 2016. Do's and don'ts in evaluation of endoscopic screening for gastrointestinal cancers. Endoscopy. 2016 Jan;48(1):75-80.
Sveen A et al. 2016. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2016 May 12;35(19):2413-27.
Guren MG et al. 2015. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. Acta Oncol. 2015 Apr 30:1-9.
Walters S et al. 2015. Is England closing the international gap in cancer survival? Br J Cancer. 2015 Sep 1;113(5):848-60.
Cameron MG et al. 2015. Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study. Radiother Oncol. 2015 Jun;115(3):314-20.
Vedeld HM et al. 2015. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers. Int J Cancer. 2015 Feb 15;136(4):844-53.
Bretthauer M et al. 2015. More adenomas – less cancer? Advanced imaging in colonoscopy. Endoscopy. 2015 May;47(5):396-7.
Robertson DJ et al. 2015. Effectiveness, training and quality assurance of colonoscopy screening for colorectal cancer. Gut. 2015 Jun;64(6):982-990.
Kaminski MF et al. 2016. Leadership training to improve adenoma detection rate in screening colonoscopy: a randomised trial. Gut. 2016 Apr;65(4):616-24.
Garborg K et al. 2015. Water exchange versus carbon dioxide insufflation in unsedated colonoscopy: a multicenter randomized controlled trial. Endoscopy. 2015 Mar;47(3):192-9.
Holme Ø et al. 2015. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut. 2015 Jun;64(6):929-36.
Spada C et al. 2015. Clinical indications for computed tomographic colonography: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline. Eur Radiol. 2015 Feb;25(2):331-45.
Bruun J et al. 2015. Regulator of chromosome condensation 2 identifies high-risk patients within both major phenotypes of colorectal cancer. Clin Cancer Res. 2015 Aug 15;21(16):3759-70.
Joranger P et al. 2015. Modeling and validating the cost and clinical pathway of colorectal cancer. Med Decis Making. 35(2):255-65.
Berstad P et al. 2015. Long-term lifestyle changes after colorectal cancer screening: randomised controlled trial. Gut. 2015 Aug;64(8):1268-76.
Dueland S et al. 2015. Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol. 2015 Jul;22(7):2195-200.
Gustavsson B et al. 2015. A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer. Clin Colorectal Cancer. 14(1):1-10.
Guren MG et al. 2014. Reirradiation of locally recurrent rectal cancer: A systematic review. Radiother Oncol. 113(2): 151–157.
Danielsen SA, Eide PW et al. 2015. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 2015 Jan;1855(1):104-21.
Leon O et al. 2014. Anal carcinoma – Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiother Oncol. 113(3):352-8.
Asli LM et al. 2014. Utilization of radiation therapy in Norway after the implementation of the national cancer plan – a national, population-based study. Int J Radiat Oncol Biol Phys. 90(3):707-14.
Holme Ø et al. 2014. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 312(6):606-15.
Ommundsen N et al. 2014. Frailty is an independent predictor of survival in older patients with colorectal cancer. Oncologist. 19(12):1268-75.
Bruun J et al. 2014. Prognostic significance of beta-catenin, E-cadherin, and SOX9 in colorectal cancer: Results from a large population-representative series. Front. Oncol. 4: 118.
Løberg M et al. 2014. Long-term colorectal-cancer mortality after adenoma removal. N. Engl. J. Med. 371(9): 799-807.
Løvf M et al. 2014. A novel transcript, VNN1-AB, as a biomarker for colorectal cancer. Int. J. Cancer 135(9): 2077-2084.
Kjersem JB et al. 2014. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. BMC Cancer 14: 340.